clinically significant medical or neurologic condition or neurocognitive dysfunction that would affect function and/or task performance and/or interfere with the study protocol
any current (or within past 2 months) medical condition requiring medication that would interact with dronabinol or interfere with the study protocol
risk of harm to self or others that requires immediate intervention
presence of contraindications, current or past allergic or adverse reaction, or known sensitivity to cannabinoid-like substances (dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)
lack of fluency in English
positive drug screen or alcohol breathalyzer
unwilling/unable to sign informed consent document
currently pregnant (positive pregnancy test), planning pregnancy, or lactating (women)
under 18 or over 50 years of age
traumatic brain injury (as defined by The American Congress of Rehabilitation as a person who has had a traumatically induced physiological disruption of brain function (i.e., the head being struck, the head striking an object, and/or the brain undergoing an acceleration/deceleration movement (i.e., whiplash) without direct external trauma to the head), as manifested by at least one of the following: any loss of consciousness; any loss of memory for events immediately before or after the injury; any alteration in mental status at the time of the incident; or focal neurological deficits that may or may not be transient)
inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report and/or a preliminary session in a mock scanner
left-handed;
presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
anticipation of a required drug test in the 4 weeks following the study.
current diagnosis of a mood, anxiety, or other disorder that is more clinically salient than PTSD
current moderate or severe alcohol/drug use disorder or in the past 8 weeks
current or past diagnosis of bipolar and other related disorders, schizophrenia spectrum, or other psychotic disorders
concomitant treatments with medication known to have drug interactions with dronabinol, such as, central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc).

NCT03008005_exc_T1
Qualifier
clinically significant
NCT03008005_exc_T2
Condition
neurologic condition
NCT03008005_exc_T3
Condition
medical condition
NCT03008005_exc_T4
Condition
neurocognitive dysfunction
NCT03008005_exc_T5
Scope
medical or neurologic condition or neurocognitive dysfunction
NCT03008005_exc_T6
Temporal
current
NCT03008005_exc_T7
Temporal
within past 2 months
NCT03008005_exc_T8
Condition
medical condition
NCT03008005_exc_T9
Drug
medication
NCT03008005_exc_T10
Mood
would interact with
NCT03008005_exc_T11
Drug
dronabinol
NCT03008005_exc_T12
Mood
interfere with the study protocol
NCT03008005_exc_T13
Scope
would interact with dronabinol or interfere with the study protocol
NCT03008005_exc_T15
Condition
contraindications
NCT03008005_exc_T16
Temporal
current
NCT03008005_exc_T17
Temporal
past
NCT03008005_exc_T18
Condition
ergic or ction, o
NCT03008005_exc_T19
Condition
adverse reaction
NCT03008005_exc_T20
Condition
sensitivity
NCT03008005_exc_T21
Drug
cannabinoid-like substances
NCT03008005_exc_T22
Drug
dronabinol
NCT03008005_exc_T23
Drug
marijuana
NCT03008005_exc_T24
Drug
cannabis
NCT03008005_exc_T25
Drug
THC
NCT03008005_exc_T26
Drug
cannabinoid oil
NCT03008005_exc_T27
Drug
sesame oil
NCT03008005_exc_T28
Drug
gelatin
NCT03008005_exc_T29
Drug
glycerin
NCT03008005_exc_T30
Drug
titanium dioxide
NCT03008005_exc_T31
Scope
dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide
NCT03008005_exc_T32
Scope
allergic or adverse reaction
NCT03008005_exc_T33
Scope
current or past
NCT03008005_exc_T35
Measurement
drug screen
NCT03008005_exc_T36
Value
positive
NCT03008005_exc_T37
Measurement
alcohol breathalyzer
NCT03008005_exc_T38
Scope
drug screen or alcohol breathalyzer
NCT03008005_exc_T40
Temporal
currently
NCT03008005_exc_T41
Condition
pregnant
NCT03008005_exc_T42
Measurement
pregnancy test
NCT03008005_exc_T43
Value
positive
NCT03008005_exc_T44
Mood
planning
NCT03008005_exc_T45
Condition
pregnancy
NCT03008005_exc_T46
Condition
lactating
NCT03008005_exc_T47
Scope
currently pregnant
NCT03008005_exc_T48
Value
under 18 or over 50 years
NCT03008005_exc_T49
Person
age
NCT03008005_exc_T50
Condition
traumatic brain injury
NCT03008005_exc_T52
Condition
claustrophobia
NCT03008005_exc_T53
Condition
tolerate small, enclosed spaces without anxiety
NCT03008005_exc_T54
Mood
inability
NCT03008005_exc_T55
Negation
inability
NCT03008005_exc_T56
Procedure
self-report
NCT03008005_exc_T57
Condition
left-handed
NCT03008005_exc_T58
Device
ferrous-containing metals
NCT03008005_exc_T59
Device
aneurysm clips
NCT03008005_exc_T60
Device
shrapnel
NCT03008005_exc_T61
Device
retained particles
NCT03008005_exc_T62
Scope
aneurysm clips, shrapnel/retained particles
NCT03008005_exc_T63
Temporal
in the 4 weeks following the study
NCT03008005_exc_T64
Procedure
drug test
NCT03008005_exc_T65
Mood
anticipation of
NCT03008005_exc_T66
Condition
 o is more
NCT03008005_exc_T67
Condition
her dis is more
NCT03008005_exc_T68
Condition
disorder
NCT03008005_exc_T69
Qualifier
other
NCT03008005_exc_T70
Condition
PTSD
NCT03008005_exc_T71
Qualifier
more clinically salient than PTSD
NCT03008005_exc_T72
Scope
mood, anxiety, or other disorder
NCT03008005_exc_T73
Qualifier
moderate
NCT03008005_exc_T74
Qualifier
severe
NCT03008005_exc_T75
Condition
e disor  in the pas
NCT03008005_exc_T76
Condition
drug use disorder
NCT03008005_exc_T77
Scope
alcohol/drug use disorder
NCT03008005_exc_T78
Scope
moderate or severe
NCT03008005_exc_T79
Temporal
in the past 8 weeks
NCT03008005_exc_T80
Condition
bipolar
NCT03008005_exc_T81
Qualifier
other
NCT03008005_exc_T82
Condition
related disorders
NCT03008005_exc_T83
Condition
schizophrenia spectrum
NCT03008005_exc_T84
Condition
psychotic disorders
NCT03008005_exc_T85
Procedure
treatments
NCT03008005_exc_T86
Drug
medication
NCT03008005_exc_T87
Condition
drug interactions
NCT03008005_exc_T88
Drug
dronabinol
NCT03008005_exc_T89
Drug
central nervous system depressants
NCT03008005_exc_T90
Drug
barbiturates
NCT03008005_exc_T91
Drug
benzodiazepines
NCT03008005_exc_T92
Drug
buspirone
NCT03008005_exc_T93
Drug
lithium
NCT03008005_exc_T94
Scope
barbiturates, benzodiazepines, buspirone, lithium
NCT03008005_exc_T95
Drug
anticholinergic agents
NCT03008005_exc_T96
Drug
atropine
NCT03008005_exc_T97
Drug
scopolamine
NCT03008005_exc_T98
Drug
antihistamines
NCT03008005_exc_T99
Scope
atropine, scopolamine, antihistamines
NCT03008005_exc_T100
Scope
central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc)
NCT03008005_exc_T101
Scope
contraindications, current or past allergic or adverse reaction, or known sensitivity